Navigation Links
Hemostemix Announces US Patent Allowance
Date:6/5/2013

Kyriat Weizmann, Israel (PRWEB) June 05, 2013

Hemostemix, Ltd. (“Hemostemix”, the “Company”) announced today the issuance of a Notice of Allowance from the United States Patent and Trademark Office for a patent entitled “A Composition Comprising A Progenitor/Precursor Cell Population”.

The patent pertains to a population of cultured cells which meet certain criteria and constitute the foundation of the Company’s angiogenic (blood vessel growing) technology. The product developed on the basis of this technological platform will be used in a Phase 2 clinical trial for critical limb ischemia. The trial protocol was recently cleared by Health Canada and the trial is expected to commence later this year.

This patent is part of a broad technology platform now protected by 38 patents issued in major markets, such as the US, EU, Japan and China. The company continues to aggressively file and prosecute patents around all aspects of its technology as an important foundation for its global commercialization plans.

“The cell population which is the subject of this patent,” stated Hemostemix’ President, Dr. Valentin Fulga, “is an important pillar of our technology. This cell population is generated from a core population of cells we named Synergetic Cell Population (“SCP”), which is isolated from a simple blood collection. We believe the SCP not only has the potential to differentiate into blood vessels, but can also be transformed, through proprietary cell-culturing techniques, into other cell types, such as cardiomyocyte-like cells and neural cells.”

About Hemostemix Ltd

Hemostemix Ltd is a company incorporated in Israel with an operating research, development and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona. Hemostemix and Kwalata Trading Ltd (“Kwalata”), registered in Cyprus, are wholly-owned subsidiaries of Canadian-based parent company, Theravitae Inc (“TVI”) (together the “Hemostemix Group”). Kwalata holds the intellectual property on behalf of the Hemostemix Group. On 14 May 2013, TVI announced a letter of intent signed with Technical Ventures RX Corp (TSX-V:TIK.P) ("Technical") regarding a proposed Qualifying Transaction in which Technical would acquire TVI and its subsidiaries in a share transaction. For more information see http://www.hemostemix.com.

Read the full story at http://www.prweb.com/releases/2013Hemostemix/USPTOallowance/prweb10777870.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. The Hemostemix Group of Companies Provides Corporate Strategy Update
2. Array BioPharma Announces Pricing of Public Offering of $115 Million of Convertible Senior Notes
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Arteriocyte announces Launch of Compass Biomedical
5. TNI BioTech, Inc. Announces Death of Senior Vice President and Chief Medical Officer, Dr. Ronald Herberman
6. Elsevier Announces its Collaboration with Kasetsart University, Thailand
7. Celsion Corporation Announces $9.83 Million Registered Direct Offering
8. Caris Life Sciences Announces Planned Expansion of Next-Generation Sequencing (NGS) Capabilities
9. 3SBio Inc. Announces Completion of Merger
10. AtheroNova Announces Shipment of Phase 1 Drug Product
11. The Sidney Kimmel Foundation for Cancer Research Announces 2013 Grant Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... , ... April 27, 2017 , ... ... photonics , joined other scientists, researchers, engineers, and industry professionals in visiting U.S. ... America's ability to compete in the world photonics industry. , This year, ...
(Date:4/27/2017)...  Pendant Biosciences, Inc. (formerly Nanoferix, Inc.), a privately-held ... delivery technologies, today announced that it has been accepted ... Toronto . Shawn Glinter , ... "We are excited to become part of the JLABS ... honored to be the first Tennessee ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... Diego’s premiere team-building and cooking events company, offers one-of-a-kind gifts, ranging from gourmet ... specialize in California cuisine, and guests leave inspired with new cooking tips and ...
(Date:4/26/2017)... ... April 26, 2017 , ... Led by ex-FDA official ... trials comes to Tampa, San Francisco and Boston in 2017. The 2016 ... organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular Therapeutix Inc., Cell ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at http://www.nxt-id.com  under "SEC ... . 2016 Year Highlights: Acquisition ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
Breaking Biology News(10 mins):